Literature DB >> 12595891

Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.

X Nan1, B Peng, T-W Hahn, E Richardson, A Lizonova, I Kovesdi, M Robert-Guroff.   

Abstract

A strategy to circumvent immune responses to adenovirus (Ad) resulting from natural infection or repeated vector administrations involves sequential use of vectors from different Ad serotypes. To further develop an Ad-HIV recombinant AIDS vaccine approach, a replication-defective recombinant Ad from a non-subgroup C virus was required. Using a cosmid system, we generated an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus and compared expression of the inserted HIV genes with a similarly constructed replication-competent Ad7deltaE3HIV(MN)env/rev recombinant. Ad7deltaE1deltaE3HIV(MN)env/rev expressed both HIV env and rev gene products. The envelope protein was correctly processed and functional, mediating syncytia formation of Ad7deltaE1deltaE3HIV(MN) env/rev-infected cells and CD4(+) T lymphocytes. Ad7deltaE1deltaE3HIV(MN)env/rev could be amplified on 293-ORF6 cells, containing the E4 ORF6 gene, shown earlier to support production of an Ad7 vector lacking the E1a gene. The utility of this cell line is now extended to the production of replication-defective Ad7 recombinants lacking E1a, E1b, and protein IX genes. Sequential immunizations with Ad-HIV recombinants based in different Ad serotypes have been shown to effectively elicit both humoral and cellular HIV-specific immune responses. The recombinant Ad7deltaE1deltaE3HIV(MN)env/rev will be useful in such AIDS vaccine strategies. Further, these studies have created new cosmid vectors that can be applied to generation of single- or double-deleted Ad7 recombinants with foreign genes inserted into the E1 and/or E3 regions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595891     DOI: 10.1038/sj.gt.3301903

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

Review 2.  Getting genetic access to natural adenovirus genomes to explore vector diversity.

Authors:  Wenli Zhang; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-07-15       Impact factor: 2.332

3.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

4.  Development and assessment of human adenovirus type 11 as a gene transfer vector.

Authors:  Daniel Stone; Shaoheng Ni; Zong-Yi Li; Anuj Gaggar; Nelson DiPaolo; Qinghua Feng; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.

Authors:  Bo Peng; Liqun Rejean Wang; Victor Raúl Gómez-Román; Alberta Davis-Warren; David C Montefiori; V S Kalyanaraman; David Venzon; Jun Zhao; Elaine Kan; Thomas J Rowell; Krishna K Murthy; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Characterization of human adenovirus 35 and derivation of complex vectors.

Authors:  Duncan McVey; Mohammed Zuber; Damodar Ettyreddy; Christopher D Reiter; Douglas E Brough; Gary J Nabel; C Richter King; Jason G D Gall
Journal:  Virol J       Date:  2010-10-19       Impact factor: 4.099

Review 7.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

8.  Adenoviral producer cells.

Authors:  Imre Kovesdi; Susan J Hedley
Journal:  Viruses       Date:  2010-08-16       Impact factor: 5.818

9.  Applying genomic and bioinformatic resources to human adenovirus genomes for use in vaccine development and for applications in vector development for gene delivery.

Authors:  Jason Seto; Michael P Walsh; Padmanabhan Mahadevan; Qiwei Zhang; Donald Seto
Journal:  Viruses       Date:  2010-01-06       Impact factor: 5.818

10.  Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.

Authors:  Xiaobo Su; Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Rong Zhou
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.